Alzprotect, established in 2007 in Lille, France, focuses on creating therapies to slow or halt neurodegenerative diseases and rejuvenate brain function. Alzprotect is dedicated to innovating in the neurodegenerative field. The company holds 4 international patent families for its developed drugs and their global indications.

Alzprotect is making strides with AZP2006 (EZEPROGIND), a novel oral synthetic molecule aimed at enhancing lysosome homeostasis by regulating Progranulin and its chaperone protein, Prosaposin. Unlike traditional treatments that target symptoms like amyloid peptides or Tau protein, AZP2006 focuses on the root processes of neurodegeneration. It has shown promising results in reducing amyloid peptide secretion, lowering hyperphosphorylated Tau protein levels, and decreasing neuroinflammation, thus offering a comprehensive treatment approach. Granted « orphan drug » status in Europe and the US for Progressive Supranuclear Palsy (PSP), its safety and efficacy have been proven in human trials, paving the way for Phase 2B/3 trials for PSP and future applications in Parkinson’s disease, Alzheimer’s disease, and amyotrophic lateral sclerosis.

–  Therapeutic areas: Neurodegenerative diseases, Alzheimer’s disease, Progressive Nuclear Palsy, Parkinson’s disease

–  Based in: Loos (FRANCE), Boston (US)

–  Employees: 1 – 10

– Created in: 2007